Introduction
Allelic loss of the short arm of chromosome 17 is among the most commonly recognized genetic alterations in human breast cancer (reviewed by Bieche and Lidereau, 1995) . This chromosomal loss occurs even more frequently in breast cancer than do mutations of the p53 tumor suppressor gene, which resides at 17p13.2 (Cornelis et al., 1994; Deng et al., 1994) . Furthermore, for some cases of breast cancer the 17p allelic loss is limited to a telomeric portion of the chromosome that excludes the p53 locus (Andersen et al., 1992; Coles et al., 1990; Sato et al., 1991) . Consequently, it has been proposed that one or more tumor suppressor genes may reside telomeric to p53 on 17p.
A candidate tumor suppressor gene, HIC-1 (hypermethylated in cancer), was recently identi®ed because of its association with a CpG rich region, or CpG island', at 17p13.3 that is aberrantly hypermethylated and transcriptionally inactivated in several common types of human cancer, including breast cancer cell lines (Makos-Wales et al., 1995) . The entire HIC-1 coding region and the 5'¯anking region are encompassed within the`CpG' island. Amino acid sequence analysis has revealed the gene product to have ®ve Kruppel-type Cys 2 -His 2 zinc-®ngers and a zinc-®nger N-terminal (Zin) domain characteristic of a subset of zinc-®nger transcription factors (Albagli et al., 1995) that includes two proteins found because they are involved in translocations in human neoplasias (Chen et al., 1993; Miki et al., 1994) . In addition, sequence analysis has revealed a p53 binding site in the 5'¯anking region and functional studies have demonstrated, in a colon cancer cell line, activation of HIC-1 transcription by p53. Finally, transfection of the gene into cultured breast, colon, and brain cancer cells has been found to suppress cell growth (MakosWales et al., 1995) .
While these experiments support the role of HIC-1 as a tumor suppressor gene, the extent of HIC-1 gene hypermethylation, and relationship of methylation to allelic loss and gene transcriptional inactivation in primary breast cancer has not been previously explored. The purpose of this study was to determine the frequency of HIC-1 methylation in primary in®ltrating breast cancers and to correlate this event with the level of HIC-1 gene expression. The set of tumors used in this study were also de®ned with regard to allelic loss of the 17p12-tel locus, and in some cases, to mutations of the p53 gene. restriction sites (each with 2 CpG dinucleotides) over the 11 kb region that encompasses the HIC-1 gene compared to the average frequency in the genome of one NotI site every 150 kb. In addition, there are 16 EagI sites (each with 2 CpG dinucleotides) scattered throughout the HIC-1 coding region, and 33 HhaI sites (each with 1 CpG dinucleotide) clustered around the 5' part of the gene (Figure 1 ). To study methylation of the HIC-1 gene, samples were digested with each of the above methylation-sensitive enzymes (HhaI, EagI, NotI) in combination with¯anking enzymes (EcoRI or PstI) and analysed by Southern blots. For EcoRI/ NotI digested samples probed with ynz22, unmethylated DNA was represented by polymorphic bands of 4.5 ± 5 kb, due to a variable length repeat within the ynz22 region.
Our initial ®nding in the present study was an unusual pattern of methylation for HIC-1 in normal breast epithelium. Whereas HIC-1 is completely unmethylated in most normal tissues (for example, sample B59NS in Figure 2b representing normal skin), samples of normal breast ducts microdissected from fresh-frozen tissues (for example, sample B59NB in Figure 2b ) were found to have dense methylation of approximately one-half of HIC-1 and no methylation of the remaining HIC-1. The dense methylation involves NotI sites N3 through N7; on Southern blot these methylated alleles are represented by an EcoRI/ NotI fragment of approximately 12 kb compared to fragments of 4 ± 5 kb for the unmethylated alleles. The pattern of both densely methylated and completely unmethylated alleles was also seen in all samples of breast epithelial cells puri®ed from reduction mammoplasty specimens (Figure 2b , samples N56, N87, N90, N91). A similar result can be seen in these normal breast duct samples for HhaI sites, where small fragments representing unmethylated alleles and a larger (approximately 2 kb) PstI¯anking fragment representing alleles with methylation of all HhaI sites are present (for example, samples 2292NB, B105NB, B106NB, and B107NB in Figure 2c ). All 16 EagI sites (data not shown) were also simultaneously involved (i.e., 50% completely methylated and 50% completely unmethylated) in each of these samples.
Our data implies that the combination of both densely methylated HIC-1 alleles and unmethylated HIC-1 alleles in normal breast duct epithelial cells is a result of preferential methylation of a speci®c HIC-1 allele. We base this interpretation on frequent observations of two distinct unmethylated alleles seen with the polymorphic ynz22 marker in samples of most normal tissues, while normal breast ducts typically displayed only a single unmethylated allele (for example, compare B59NS to B59NB). This pattern suggests that the unmethylated HIC-1 in the normal breast originates from one of the two HIC-1 alleles, and only one allele remains unmethylated.
The methylation pattern of the HIC-1 gene in most breast cancers distinctly diered from that seen in normal breast epithelium. In 26 of 39 tumors, an extensive methylation of all HIC-1 alleles was seen (for example, for NotI sites, compare normal breast sample B59NB to paired tumor B59T in Figure 2b , and for HhaI sites, compare normal breast B107NB to paired Figure 1 Diagram of the HIC-1 gene region. The PstI, EcoRI, NotI, HhaI and EagI sites and ynz22 and probe 500 marker sites are diagramed with relationship to the HIC-1 gene coding sequences and p53 binding site detected by digestion of DNA with EcoRI/NotI, electrophoresis and transfer, and probing with ynz22. DNA unmethylated at all NotI sites are marked by small arrows, DNA methylated at all NotI sites are marked by large arrows, and bands for DNA methylated at some NotI sites are marked by arrowheads to right of ®gure. The samples are designated by case number suxed by tissue of origin: i.e. normal breast ductal tissue (NB), normal skin tissue (NS), tumor tissue (T), and metastasis (M). Tissues B59NS and BH6T were considered to have no methylation of weak methylation. Tissues B59NB, BH9T, and BH10T were considered to have moderate methylation. Other tissues were considered to have strong methylation (compared to normal breast). (c) Methylation of HIC-1 detected by digestion of DNA with PstI/ HhaI, electrophoresis and transfer, and probing with probe 500. Bands for unmethylated and methylated DNA, and the tissues of origin for the samples are marked as above. Tissues B106T, BH4T, and BH6T were considered to be unmethylated. Tissues 2292NB, B105NB, B106NB, B107NB were considered to have moderate methylation. Other samples were considered to be strongly methylated tumor B107T in Figure 2c ). Tumor BH11T is notable in that it is strongly methylated at variable members of NotI sites, in contrast to most other tumors which appear to be methylated at all NotI sites.
We found that even for tumors with extensive methylation of HIC-1, a weak band indicative of unmethylated DNA was commonly observed. We believe that residue contamination by DNA from lymphocytes or stromal cells could account for a substantial portion, if not all, of the unmethylated DNA seen in these tumor samples. It is important to recognize that in this analysis, normal cells with two unmethylated alleles would often be relatively overrepresented compared to tumor cells with LOH at the HIC-1 locus and only a single methylated allele.
Seven other tumors were found to be methylated at levels similar to those of normal breast epithelium. These cases are designated as moderate methylation in Table 1 , and are represented by cases BH9T and BH10T in Figure 2 . Five of these seven cases were found to have LOH of 17p, leading us to conclude that some tumors may be heterogeneous with respect to methylation of a single HIC-1 allele. Finally, no methylation of HIC-1 was noted in six cases, including BH4T, BH6T, and B106T which are demonstrated in Figure 2 . All six of these cases were found to have LOH of 17p, presumably aecting a methylated HIC-1 allele.
Allelic loss of 17p
Alellic loss for the chromosomal region 17p12 ± 17ptel was de®ned by loss of a band hybridizing to ynz22 on Southern blot (for cases informative for this marker) or by ampli®cation of only one allele for informative microsatellite markers¯anking the region. In 33 of the 39 (85%) cases, we found allelic loss of all informative markers; no cases were found to have loss of only a portion of this region of 17p. Autoradiograms of representative cases are presented in Figure 2 and the data is summarized in Table 1 .
Dense methylation of HIC-1 was observed in 22 of the 33 tumors with 17p allelic loss (for examples B59T, B73T, BH12T, B107T, BH1T, BH11T, BH12T, BH14T, B95T, B83M and B84T in Figure 2b and c). Dense methylation was also observed in four of six tumors with no evidence of 17p allelic loss (for example, B78T in Figure 2c ), suggesting that complete methylation of both alleles is also a mechanism for HIC-1 inactivation in breast cancer.
Expression of HIC-1 mRNA
Some of the primary breast cancer cases had a morphologic pattern amenable to rapid microdissection of the frozen tissue, and these cases were used for RNase protection studies of HIC-1 mRNA expression. As shown in Figure 3 , all of the microdissected normal breast duct tissues were found to have detectable HIC-1 expression. In addition, HIC-1 expression was observed for two tumors (BH4 and B127) which did not have methylation of the HIC-1 gene. In contrast, for three tumor samples (B95, B107, and B105) with extensive HIC-1 methylation, no expression of the gene could be detected. One exception to this general pattern was that of case B106 which did ont show methylation of the HIC-1 gene and additionally did not demonstrate expression of HIC-1 mRNA. This case is also notable in that it has a missense mutation of the p53 gene. Since in a colon cancer cell line, HIC-1 expression has been shown to be activated by expression of an exogenous p53 gene, we reason that the loss of HIC-1 expression in this case could be a result of the mutated p53.
Sequence analysis of p53 exons 5 ± 8
The p53 gene exons 5 ± 8 of all six cases with 17p LOH and unmethylated HIC-1 were sequenced using direct PCR sequencing. Two of these cases were found to have base substitutions that would be expected to result in missense mutations: case BH10T was found to have a C to G mutation at codon 282 (exon 8), and case B106 was found to have a G to A mutation at codon 175 (exon 5). Exons 5 ± 8 of p53 gene were sequenced in an additional six cases, all with 17p LOH and HIC-1 methylation and no mutations were found among these cases. Figure 3 mRNA expression of HIC-1 in normal breast ducts and breast cancer. RNA probes for HIC-1 and GAPDH were hybridized to electrophoresed RNA from designated samples and digested with RNase. Arrowhead marks protected HIC-1 transcript; protected GAPDH transcript is seen as strong lower band. Samples B59NB, B79NB, B106NB, BH4T, and B127T were interpreted as expressing HIC-1
Discussion
Inactivation of tumor suppressor genes is thought to most often involve mutation of one copy of the gene and loss of the corresponding normal allele (Cavenee, 1991 ). An alternative mechanism for tumor suppressor gene inactivation has been proposed for some tumor suppressor genes, whereby one or both copies of a gene are inactivated in association with hypermethylation of CpG islands in the 5' gene transcriptional promoting region (Cross and Bird, 1995) . Examples of tumor suppressor genes found to be inactivated with such methylation include the VHL gene, which is hypermethylated in many cases of renal cell carcinoma (Herman et al., 1994) , the MTS/p16 gene, which has been found to be hypermethylated in a signi®cant portion of lung, brain, head and neck, and breast cancers (Merlo et al., 1995) , and the p15 gene which is hypermethylated in acute myelogenous leukemia and other hematologic malignancies (Batova et al., 1997; Herman et al., 1997) . Whereas VHL and MTS-1/p16 were both initially established as tumor suppressor genes by linkage to hereditary cancers and by ®ndings of tumor speci®c somatic mutations, the HIC-1 candidate tumor suppressor gene was identi®ed by cloning of a 17p13.3 chromosomal region which contained a dense CpG island that is hypermethylated in tumor cell DNA (Makos-Wales et al., 1995) . The HIC-1 gene has been found to be extensively methylated in primary glioblastomas, colon and renal cell carcinomas (Makos et al., 1992 (Makos et al., , 1993a and in cell lines derived from cancers of the brain, breast, colon and lung (Makos-Wales et al., 1995) . In established cell lines, this methylation has been found to be associated with transcriptional inactivation of the gene (Makos-Wales et al., 1995) .
The purpose of the present study was to determine the extent and frequency of HIC-1 methylation and inactivation in primary breast cancer. We ®nd that dense methylation of the HIC-1 gene and probable absense of expression of this gene, are characteristic of a large number (67%) of primary breast cancers. Surprisingly, however, we also found all normal breast ductal tissues to have approximately equal amounts of densely methylated HIC-1 and completely unmethylated HIC-1 alleles. The only other normal tissue where such a pattern for hemi-methylation of HIC-1 has been observed is the normal prostate epithelium (Morton et al., 1996) .
Only two other situations have been previously found with hemi-methylation of CpG islands associated with the 5' region of genes: inactivation of one copy of x-chromosome alleles in females (Riggs and Pfeifer, 1992) and imprinting of autosomal genes (Razin and Cedzar, 1994) , where the silenced and expressed alleles are parentally determined. Determining whether the HIC-1 gene is parentally imprinted in the speci®c tissues where it is hemi-methylated, such as breast and prostate, will require the analysis of methylation patterns in breast or prostate tissues obtained from multiple family members. Accessible tissues such as blood cells, skin, and colon mucosa would not be useful for such studies because HIC-1 is fully unmethylated in these tissues. Based on our present data, however, it appears likely that expression of HIC-1 in normal breast epithelium results from transcriptional activity of one of two alleles in this tissue. If loss of HIC-1 expression contributes to the evolution of cancer, then tissues such as breast and prostate are at high risk for this event since one HIC-1 allele is constitutively inactivated by methylation. Thus, only one step would be required for HIC-1 inactivation in such tissues; this could occur either via preferential loss of an unmethylated, transcriptionally active allele in the tumor, or by de novo methylation of the remaining allele in the tumor cells without 17p LOH.
Because HIC-1 is not always hypermethylated in breast cancers with 17p LOH, we have considered the possibility that LOH of 17p is associated with either inactivation of HIC-1 or inactivation of another tumor suppressor gene on the same chromosomal arm. Most signi®cantly, the p53 gene resides at 17p12.2 and we questioned whether breast tumors with 17p LOH but without HIC-1 inactivation may have an associated mutation of the p53 gene. We found p53 mutations in only two of these six cases, and in one of the six breast tumors with 17p LOH and HIC-1 methylation that we examined. Notably, approximately 20% of p53 mutations in breast cancer have been found in exons 1 ± 4 or 9 ± 10 (Greenblatt et al., 1994) , and therefore we may have not detected all p53 mutations in these cases. However, it appears likely that LOH of 17p in some cases of breast cancer may be associated with neither p53 mutation nor HIC-1 methylation. Two other candidate tumor suppressor genes, OVCA1 (also designated DPH2L (Phillips et al., 1996) and OVCA2 (Schultz et al., 1996) , have been identi®ed at the 17p13.3 locus. These genes were found to be expressed at low or undetectable levels in most ovarian tumors and cell lines, although they are expressed in normal cells of various origins, including surface epithelial cells of the ovary. OVCA1 and OVCA2 are located approximately 1 kb centromeric to the HIC-1 gene, and transcribed strands of all three genes are oriented in the same direction. Methylation of a 5'-CpG island may also regulate expression of OVCA1 and OVCA2 for ovarian cancer, but preliminary studies have found the extent of OVCA2 methylation to be similar for normal breast ducts and breast cancer tissues (data not shown). Further work will be needed to determine the full extent of inactivation of these genes in breast cancer and possible relationships between OVCA1 or OVCA2 inactivation, HIC-1 inactivation, and LOH of 17p.
In summary, our present study demonstrates frequent methylation and transcriptional inactivation of HIC-1 in breast cancer. Although HIC-1 is transcriptionally active in the normal breast ductal epithelium, this tissue could be predisposed to inactivation of HIC-1 as a result of dense methylation of one allele. Recently, we have found evidence for LOH of 17p to be one of the early events in the evolution of ductal carcinoma in situ (Fujii et al., 1996a) and therefore our present ®ndings suggest that methylation-associated inactivation of HIC-1 could well be an early tumor suppressor inactivation event in breast cancer pathogenesis.
Materials and methods

Tissue microdissection
In®ltrating breast cancer tissues (39 cases), surrounding normal breast tissue (®ve cases) and breast from reduction mammoplasty (three cases) were snap frozen at the time of collection and stored at 7808C until used for these studies. Frozen sections of the tissues were stained with hematoxylin and eosin and microdissected as described previously (Fujii et al., 1996b) . After microdissection, the desired tissue component (tumor cells or normal ductal cells) comprised at least 80% of the sample. DNA was then phenol-chloroform extracted after SDS/proteinase K digestion of the tissue. Microsatellite studies were performed on DNA isolated from these frozen tissues, or from paran blocks of the same cases, as previously described (Fujii et al., 1996b) . For extraction of RNA, microscopic slides, microtome blades, and other instruments were precleaned with RNase Zap (Ambion, Austin, TX), and sections were stained brie¯y with ethanol-based eosin and rinsed in solutions that had been previously treated with diethyl pyrocarbonate (Sigma Chemical Co., St. Louis). These frozen sections were also submitted to direct microdissection, with each slide limited to 1/2 h of dissection time to limit the degradation of the mRNA. mRNA from the dissected tissues was then solubilized using Trizol (Gibco/BRL, Gaithersburg, MD).
Isolation of breast duct organoids
Organoids containing human mammary epithelial cells were prepared from reduction mammoplasty specimens by the method of Stamfer (1985) . Breast tissue from reduction mammoplasty were dissected and enzymatically digested into duct-like structures (organoids), ®ltered to retain only organoids, and frozen at 7708C until used. Samples of the organoids were also examined histologically and con®rmed to consist of at least 80% epithelial cells.
Methylation of the HIC-1 gene
To study methylation of the HIC-1 gene, DNA samples (10 mg/reaction) were digested with methylation-sensitive enzymes (HhaI, EagI, NotI) in combination with¯anking enzymes (EcoRI or PstI) using buers supplied by and conditions recommended by the manufacturer (Gibco/ BRL). Digested DNA was separated in 1 ± 1.2% agarose gels, transferred to nylon membrane, and probed with radiolabelled ynz22 or probe 500 marker. Figure 1 demonstrates the structure of the HIC-1 gene region, the positions of the ynz22 and probe 500 markers, and the restriction enzyme sites.
Allelic analysis of 17p
Analysis for the presence of alleles at the HIC-1 locus was performed by Southern analysis with the ynz22 marker, by microsatellite markers¯anking the HIC-1 region, or both.
Microsatellite markers for the telomeric portion of 17p (D17S122, TP53, CHRNB1, D17S513, D17S926) were purchased from Research Genetics (Huntsville, AL). DNA derived from normal and tumor microdissected tissues were PCR ampli®ed using conditions previously described. PCR products were separated by acrylamide gel electrophoresis and allelic loss was scored when one allele decreased in intensity at least 70% compared to normal.
RNAse protection assay for analysis of HIC-1 transcription Only cases from which tumor could be easily microdissected were used for these studies. This selection was made because of the need to minimize the time of dissection and maximally preserve mRNA. Total RNA (approximately 10 mg) was hybridized with the 360 bp cosmid subclone 600 HIC-1 RNA probe (Makos-Wales et al., 1995) , digested with RNAse A, and separated by a 6% denaturing polyacrylamide gel. RNA was cohybridized with anti-sense 250 bp GAPDH RNA probe. Preparation of the RNA probes and RNAse protection were performed using Ambion MAXIscript and HybSpeed RPA using manufacturers' recommended protocols.
p53 mutational analysis
Exons 5, 6, 7 and 8 of the p53 gene were PCR ampli®ed using primers designed from the published sequence of the gene. (Exon 5F: GTCTCCTTCCTCTTCCTACAG, 5R: TCTCCAGCCCCAGTGCTCA, 6F: GGCCTCTGATTC-CTCACTGATT, 6R: AGAGACCCCAGTTGCAAACC, 7F: CTCATCTTGGGCCTGTGTTATC, 7R: AGGGGT-CAGCGGCAAGCAGA, 8F: TGCTTCTCTCTTTTC-CTATCCTGA, 8R: CGCTTCTTGTCCTGCTTGCT). Taq polymerase was added to prewarmed reaction tubes (hot start), and 42 cycles of PCR were conducted using annealing temperatures of 60 ± 648C. Double stranded PCR products were agarose gel puri®ed (Mermaid Kit, BIO 101, Vista, CA) and sequenced by labelling with 35 S-dATP in reactions containing individual forward and reverse primers and T7 Sequenase version 2.0 DNA polymerase (United States Biochemical, Cleveland, OH). Aliquots of each labelling reaction were added to termination tubes (G, A, T and C) and incubated at 378C for 5 ± 10 min. Reactions were stopped and samples electrophoresed on a 6% denaturing acrylamide gel.
Abbreviations
LOH=loss of heterozygosity, PCR=polymerase chain reaction.
